Federal Contractor Profile
Eitr Biologics, INC.
$36M obligated·8 awards·2 agencies·2 NAICS
Federal Contracts
Showing contracts 1–16 of 16 total. Sorted by action date, most recent first. Excludes $0 modifications.
| Date | Agency | PIID | NAICS | Description | Amount |
|---|---|---|---|---|---|
| Jul 15, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50123C00060 | 541714 | THE DEVELOPMENT OF A MULTIMODAL ANTIBODY PLATFORM TO EXTEND THE WINDOW OF IMMUNOTHERAPEUTIC INTERVENTION. THE OVERALL OBJECTIVE OF THE WORK OUTLINED IN THIS CONTRACT IS TO CRITICALLY EVALUATE THE UTILITY OF THE VHH AS A PLATFORM MCM TECHNOLOGY FOR VI | $4.6M |
| Jul 2, 2025 | Department of DefenseARMY MED RES ACQ ACTIVITY | HT942524F0269 | 541714 | NOVEL NANOTHERAPEUTICS | $424K |
| May 19, 2025 | Department of DefenseARMY MED RES ACQ ACTIVITY | HT942525F0221 | 541714 | NOVEL NANOTHERAPEUTICS | $300K |
| May 12, 2025 | Department of DefenseARMY MED RES ACQ ACTIVITY | HT942524P0015 | 541380 | SORTING PERIPHERAL BLOOD MONONUCLEAR CELLS FROM LASSA FEVER VIRUS SURVIVORS TO DISCOVER AND PRODUCE MONOCLONAL ANTIBODIES FOR ASSESSMENT IN IN VITRO AND IN VIVO ASSAYS | $133K |
| Feb 11, 2025 | Department of DefenseARMY MED RES ACQ ACTIVITY | HT942524F0269 | 541714 | NOVEL NANOTHERAPEUTICS | $358K |
| Aug 28, 2024 | Department of DefenseARMY MED RES ACQ ACTIVITY | HT942523P0004 | 541380 | NOVEL CELL SORTING | $51K |
| Aug 24, 2024 | Department of DefenseARMY MED RES ACQ ACTIVITY | HT942524F0269 | 541714 | NOVEL NANOTHERAPEUTICS | $1.1M |
| Jul 8, 2024 | Department of DefenseARMY MED RES ACQ ACTIVITY | HT942524P0015 | 541380 | SORTING PERIPHERAL BLOOD MONONUCLEAR CELLS FROM LASSA FEVER VIRUS SURVIVORS TO DISCOVER AND PRODUCE MONOCLONAL ANTIBODIES FOR ASSESSMENT IN IN VITRO AND IN VIVO ASSAYS | $67K |
| May 16, 2024 | Department of DefenseARMY MED RES ACQ ACTIVITY | HT942524F0127 | 541714 | DEVELOP A NOVEL ODIN THERAPEUTIC MEDICAL COUNTERMEASURE CAPABLE OF PROTECTING AGAINST PNEUMONIC UNENCAPSULATED Y. PESTIS. | $500K |
| Mar 19, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50123C00060 | 541714 | THE DEVELOPMENT OF A MULTIMODAL ANTIBODY PLATFORM TO EXTEND THE WINDOW OF IMMUNOTHERAPEUTIC INTERVENTION. THE OVERALL OBJECTIVE OF THE WORK OUTLINED IN THIS CONTRACT IS TO CRITICALLY EVALUATE THE UTILITY OF THE VHH AS A PLATFORM MCM TECHNOLOGY FOR VI | $17M |
| Dec 6, 2023 | Department of DefenseARMY MED RES ACQ ACTIVITY | HT942524P0015 | 541380 | SORTING PERIPHERAL BLOOD MONONUCLEAR CELLS FROM LASSA FEVER VIRUS SURVIVORS TO DISCOVER AND PRODUCE MONOCLONAL ANTIBODIES FOR ASSESSMENT IN IN VITRO AND IN VIVO ASSAYS | $530K |
| Nov 16, 2023 | Department of DefenseARMY MED RES ACQ ACTIVITY | HT942523P0004 | 541380 | NOVEL CELL SORTING | $226K |
| Sep 22, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50123C00060 | 541714 | THE DEVELOPMENT OF A MULTIMODAL ANTIBODY PLATFORM TO EXTEND THE WINDOW OF IMMUNOTHERAPEUTIC INTERVENTION. THE OVERALL OBJECTIVE OF THE WORK OUTLINED IN THIS CONTRACT IS TO CRITICALLY EVALUATE THE UTILITY OF THE VHH AS A PLATFORM MCM TECHNOLOGY FOR VI | $9.6M |
| Aug 25, 2023 | Department of DefenseARMY MED RES ACQ ACTIVITY | HT942523F0306 | 541714 | NOVEL NANOTHERAPEUTIC APPROACHES PENETRATING THE OUTER LAYERS OF THE BACTERIUM AND TARGETING OUTER MEMBRANE PROTEINS FOR THE TREATMENT OF PNEUMONIC PLAGUE FOR ASSESSMENT IN IN VITRO AND IN VIVO ASSAYS | $750K |
| Aug 10, 2023 | Department of DefenseARMY MED RES ACQ ACTIVITY | HT942523P0004 | 541380 | NOVEL CELL SORTING | $277K |
| Nov 10, 2022 | Department of DefenseARMY MED RES ACQ ACTIVITY | HT942523P0004 | 541380 | NOVEL CELL SORTING | $552K |
Get Alerted Before Eitr Biologics, INC.'s Next Recompete
Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.
Start Free